Page last updated: 2024-12-10

vitamin d 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vitamin D2 : A vitamin D supplement and has been isolated from alfalfa. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280793
CHEMBL ID1536
CHEBI ID28934
SCHEMBL ID3420
MeSH IDM0007650

Synonyms (208)

Synonym
9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (3.beta.,5z,7e,22e)-
(1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(e,1r,4r)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol
ercalciol
vitamina d2
(3beta,5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3s,5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5z,7e,22e)-(3s)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
ergocalciferolum
CHEBI:28934 ,
(3s,5z,7e,22e)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3-beta,5z,7e,22e)-9,10-secoergosta-5,7,10,(19),22-tetraen-3-ol
ergocalciferolum [inn-latin]
9,10-seco(5z,7e,22e)-5,7,10(19),22-ergostatetraen-3-ol
d-tracetten
rodine c
geltabs vitamin d
irradiated ergosta-5,7,22-trien-3-beta-ol
haliver
9,10-secoergosta-5,7,10(19),22-tetraen-3-beta-ol
(+)-vitamin d2
rodinec
calciferolum
mina d2
ergocalciferolo [dcit]
sterogyl
hyperkil
hsdb 819
nsc 62792
vio-d
einecs 200-014-9
9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (3beta,5z,7e,22e)-
radiostol
decaps
geltabs
d-arthin
drisdol
ertron
condol
viostdrol
ergorone
nsc62792
mykostin
divit urto
fortodyl
calciferon 2
metadee
dee-ron
detalup
radsterin
vitavel-d
hi-deratol
crystallina
novovitamin-d
davitamon d
deltalin
dee-ronal
ostelin
condacaps
buco-d
crtron
mulsiferol
daral
viosterol
ergosterol, irradiated
dee-osterol
deratol
dee-roual
davitin
infron
oleovitamin d
oleovitamin d2
nsc-62792
shock-ferol
synthetic vitamin d
calciferol
diactol
condocaps
ergocalciferol (jp17/usp)
D00187
drisdol (tn)
calciferol (tn)
ACON1_002187
BPBIO1_000418
PRESTWICK_554
(5z,7e,22e)-(3s)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
LMST03010001
MEGXM0_000466
PRESTWICK3_000420
50-14-6
ergocalciferol ,
vitamin d2
C05441
ergocalciferol, 40,000,000 usp units/g
ergocalciferol (d2), analytical standard
DB00153
BSPBIO_000380
MLS001332467
smr000857106
MLS001332468
ergocalciferol, >=98.0% (sum of enantiomers, hplc)
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87 ,
oleovitamin d, synthetic
CHEMBL1536
vitamin d (ergocalciferol)
ergocalciferols
(1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
BMSE000510
irradiated ergosterol
NCGC00166307-03
NCGC00166307-02
HMS2096C22
vitamin d 2
dtxsid5020233 ,
dtxcid70233
shock-ferol sterogyl
uvesterol-d
radstein
HMS2230E20
S4035
ergocalciferol [usp:inn:ban:jan]
unii-vs041h42xc
cyclohexanol, 4-methylene-3-((2e)-2-((1r,3as,7ar)-octahydro-7a-methyl-1-((1r,2e,4r)-1,4,5-trimethyl-2-hexen-1-yl)-4h-inden-4-ylidene)ethylidene)-, (1s,3z)-
vs041h42xc ,
doral [vitamin derivative]
sorex c.r.
ergocalciferolo
disdrol
ergosterol irradiated
(3.beta.,5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
ergocalciferol [orange book]
ergocalciferol [usp-rs]
ergocalciferol [inn]
ergocalciferol [mart.]
ergocalciferol [hsdb]
ergocalciferol [ep impurity]
vitamin d2 [fcc]
vitamin d2 [who-ip]
ergocalciferol [jan]
ergocalciferol [usp monograph]
ergocalciferol, (+)-
ergocalciferolum [who-ip latin]
ergocalciferol [who-dd]
24-methyl-9,10-secocholesta-5,7,10( 19),22-tetraene-3.beta.-ol [who-ip]
ergocalciferol [who-ip]
ergocalciferol [inci]
vitamin d2 [mi]
ergocalciferol [vandf]
ergocalciferol [ep monograph]
CS-M1019
AKOS022185284
MECHNRXZTMCUDQ-RKHKHRCZSA-N
SCHEMBL3420
vitamind2
Q-201930
mfcd00166988
HY-76542
cyclohexanol, 4-methylene-3-[(2e)-2-[(1r,3as,7ar)-octahydro-7a-methyl-1-[(1r,2e,4r)-1,4,5-trimethyl-2-hexen-1-yl]-4h-inden-4-ylidene]ethylidene]-, (1s,3z)-
ergocalciferol, united states pharmacopeia (usp) reference standard
ergocalciferol, european pharmacopoeia (ep) reference standard
ergocalciferol, sigma reference standard
ergocalciferol for system suitability, europepharmacopoeia (ep) reference standard
ergocalciferol (vitamin d2), pharmaceutical secondary standard; certified reference material
vitamin d2 (ergocalciferol)
(5e,7e,22e)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
irradiated ergosta-5,7,22-trien-3beta-ol
uvesterol d
22-tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
delta-tracetten
4-methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
delta-arthin
beta-ol
vio d
osteil
9,10-secoergosta-5,7,10(19),22-tetraen-3b-ol
ergocalciferol, british pharmacopoeia (bp) reference standard
vitamin d2; ergocalciferol; deltalin
sterogyl-15
lanes
osto-d2
eciferol d2
d-forte
bdbm50247883
ergoral d2
sterogyl 15h
ergo-d2
AS-11649
9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (3b,5z,7e,22e)-
Q139200
CCG-268614
(s,z)-3-((e)-2-((1r,3as,7ar)-1-((2r,5r,e)-5,6-dimethylhept-3-en-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol
BP-31119
ergocalciferol; 50-14-6
(1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
EN300-21690916
24-methyl-9,10-secocholesta-5,7,10(19),22-tetraene-3beta-ol
cyclohexanol, 4-methylene-3-(2-(tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene)ethylidene)-
ergocalciferol (usp:inn:ban:jan)
ergocalciferolum (inn-latin)
ergocalciferol (ep monograph)
a11cc01
ergocalciferol (mart.)
vitaminum d2
ergocalciferol (ep impurity)
ergocalciferol capsules,
ergocalciferol (usp-rs)
9,10,secoergosta-5,7,10(19),22-tetraen 3-beta-ol
9,10-secoergosta-5,7,10(19),22-tetraen-3-ol,(3-beta,5z,7e,22e)-
ergocalciferol (usp monograph)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LD50 for IalphaOHD3 was equal to 100 microgram/kg, if it was administered during 5 days per os."( [Comparative study of the biological activity and toxic effect of 1alpha-hydroxycholecalciferol and ergocalciferol in rats].
Avakumov, VM; Blazheevich, NV; Bogoslovskiĭ, NA; Samokhvalov, GI; Spirichev, VB,
)
0.13
" We conclude that alpha-calcidol is more toxic than calcitriol in the mouse and suggest that the degree of toxicity is correlated to the degree of hypercalcemia and to the vitamin D metabolite used."( The comparative toxicity of vitamin D metabolites in the weanling mouse.
Cole, DE; Crocker, JF; Hamilton, DC; Muhtadie, SF, 1985
)
0.27
" Such treatment is safe and not accompanied by a serious risk of hypercalcaemia or renal impairment."( Safety of treatment for subclinical osteomalacia in the elderly.
Boyd, RV; Campbell, GA; Cotton, RE; Hosking, DJ; Kemm, JR, 1984
)
0.27
" There was no significant difference in adverse events between the paricalcitol and placebo-treated groups."( 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Abboud, H; Gellens, M; González, EA; Hamm, LL; Lindberg, J; Martin, KJ, 1998
)
0.3
" Adverse events that were considered by the investigator to have a possible."( A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR, 2001
)
0.31
"This long-term study of paricalcitol demonstrates that it rapidly and effectively suppresses iPTH levels in a wide spectrum of ESRD patients and caused no unexpected adverse events."( A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR, 2001
)
0.31
" Topical active vitamin D compounds have proven to be both safe and effective for treating psoriasis."( Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic, C; Holick, MF; Ray, S, 2004
)
0.32
"Once-daily application of paricalcitol ointment was safe and effective for the treatment of plaque psoriasis."( Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study.
Durakovic, C; Holick, MF; Ray, S, 2004
)
0.32
" Studies have not yet defined the optimal dose and duration of vitamin D necessary to replete and maintain stores in dialysis patients, or whether it is safe or beneficial."( Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.
Coyne, DW; Giles, K; Gincherman, Y; Norwood, K; Saab, G; Young, DO, 2007
)
0.34
"We conclude that the vast majority of hemodialysis patients are vitamin D-deficient; monthly ergocalciferol 50,000 IU is safe and effective in normalizing serum 25(OH)D levels and may have an epoetin-sparing effect."( Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.
Coyne, DW; Giles, K; Gincherman, Y; Norwood, K; Saab, G; Young, DO, 2007
)
0.34
"Active and less toxic vitamin D analogs could be useful for clinical applications."( Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model.
Filip, B; Kutner, A; Milczarek, M; Nevozhay, D; Wietrzyk, J, 2008
)
0.35
"The LD50 values after five daily subcutaneous (s."( Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model.
Filip, B; Kutner, A; Milczarek, M; Nevozhay, D; Wietrzyk, J, 2008
)
0.35
" Pharmacists also should be familiar with possible toxic effects of vitamin D, particularly as public awareness of benefits continues to increase."( Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity.
Cappuzzo, KA; Carlton, S; Clopton, D, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"We confirm that paricalcitol suppresses iPTH and lowers proteinuria in patients with stage 2-5 CKD without an increased risk of adverse events."( Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Chen, J; Cheng, J; Li, X; Zhang, W; Zhang, X, 2012
)
0.38
" Other adverse events were similar between groups."( Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ching, CH; Ghazali, A; Ghazalli, R; Goh, BL; Goh, HK; Manocha, AB; Mohamad, S; Narayanan, P; Omar, M; Ong, LM; Rahmat, K; Seman, MR; Shaariah, W; Shah, S; Vaithilingam, I, 2013
)
0.39
" Adverse events were higher in children who received placebo than in those administered paricalcitol during the double-blind treatment (88."( Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Ariceta, G; Dell, KM; Dufek, MB; Eldred, A; Greenbaum, LA; Hoppe, B; Lee, HJ; Lerner, G; Linde, P; Warady, BA; Webb, NJA, 2017
)
0.46
"Recent randomized controlled trials (RCTs) provide evidence for a possible beneficial impact of vitamin D supplementation on health outcomes beyond bone health, but there are few reviews of noncalcemic adverse effects from long-term supplementation."( Noncalcemic adverse effects and withdrawals in randomized controlled trials of long-term vitamin D2 or D3 supplementation: a systematic review and meta-analysis.
Malihi, Z; Mm Lawes, C; Scragg, R; Wu, Z, 2017
)
0.46
"The aims of this systematic review of vitamin D supplementation in RCTs were as follows: to determine whether all adverse effects, when combined, are reported equally between treatment arms; to identify the most common noncalcemic adverse effects reported; and to ascertain whether withdrawal rates, as a marker of clinical adverse effects, differ between treatment arms."( Noncalcemic adverse effects and withdrawals in randomized controlled trials of long-term vitamin D2 or D3 supplementation: a systematic review and meta-analysis.
Malihi, Z; Mm Lawes, C; Scragg, R; Wu, Z, 2017
)
0.46
"Overall, these findings suggest that vitamin D, by itself, does not increase the risk of noncalcemic adverse effects."( Noncalcemic adverse effects and withdrawals in randomized controlled trials of long-term vitamin D2 or D3 supplementation: a systematic review and meta-analysis.
Malihi, Z; Mm Lawes, C; Scragg, R; Wu, Z, 2017
)
0.46
" No significant differences were observed in the incidence of hypercalcemia, hyperphosphatemia, or adverse events."( A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
Geng, X; Shi, E; Song, Y; Wang, S, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Compared with previous pharmacokinetic studies in HD patients, plasma concentrations (100 to 250 pg/mL) during the 4-hour period were consistent with predicted values for this dose, and there was no apparent increase in paricalcitol clearance during HD."( Effect of hemodialysis on the pharmacokinetics of 19-nor-1alpha,25-dihydroxyvitamin D2.
Cady, WW; Cato, A; Chang, M; Qasawa, B; Soltanek, C; Stoll, R, 1998
)
0.3
"This is the first detailed pharmacokinetic report published on the administration of doxercalciferol [1alpha(OH)D(2)] recently introduced to treat secondary hyperparathyroidism."( Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.
Bishop, CW; Knutson, JC; LeVan, LW; Upton, RA, 2003
)
0.32
"02 ng/ml) and paricalcitol pharmacokinetic parameters were estimated using non-compartmental methods."( Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.
Awni, W; Chan, J; Chira, T; Galitz, L; Palaparthy, R; Pradhan, RS; Rieser, M; Williams, LA, 2007
)
0.34
" This post hoc analysis of a Phase 3 study evaluated the pharmacodynamic effects of the iron-based phosphate binder sucroferric oxyhydroxide (SFOH) and sevelamer (SEV) carbonate on VDRA activity in dialysis patients."( Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM, 2016
)
0.43
" Potential interactions of SFOH and SEV with VDRAs were assessed using serum intact parathyroid hormone (iPTH) concentrations as a pharmacodynamic biomarker."( Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM, 2016
)
0.43
" The current work describes a population pharmacokinetic (PK) model for D2 and 25OHD2 and the use of a previously developed D3-25OHD3 PK model [1] for comparing D3 and D2-related exposures."( Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics.
Gastonguay, MR; Ocampo-Pelland, AS; Riggs, MM, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"76 years, were treated in the course of one year with sodium fluoride (Fluosen) in a dose of 45 mg/24 h in combination with calcium gluconate (2 g/24 h) and oil solution of vit D2 (2 mg/week)."( [Treatment of patients with postmenopausal and steroid-induced osteoporosis using sodium fluoride combined with vitamin D2 and calcium gluconate].
Andreeva, M; Diankova, L; Kamenova, P; Khristova, D; Todorova, S; Tsachev, K, 1990
)
0.28
" Paricalcitol, when combined with As2O3, showed a markedly enhanced antiproliferative effect against acute myeloid leukemia (AML) cells."( 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Desmond, JC; Hewison, M; Hughes, SV; Koeffler, HP; Kumagai, T; O'Kelly, J; Shih, LY, 2005
)
0.33
"The authors undertook a phase 1 study of gemcitabine in combination with escalating doses of paricalcitol administered weekly intravenously in patients with advanced cancers."( A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"Changes in the concentrations of vitamin D and its metabolites in plasma of healthy subjects orally given physiological doses of vitamin D2 by multivitamin or vitamin D liquid preparations were determined and the bioavailability of vitamin D was studied."( Changes in the concentrations of vitamin D and its metabolites in the plasma of healthy subjects orally given physiological doses of vitamin D2 by multivitamin or vitamin D preparations.
Itokawa, Y; Kobayashi, T; Masuda, S; Matsuoka, M; Okano, T; Otsuka, H; Takeuchi, T, 1989
)
0.28
" Thus, in a northern American population we cannot demonstrate that reduced bioavailability of vitamin D plays a major role in age-related bone loss."( Effect of aging on vitamin D stores and bone density in women.
Kumar, R; Melton, LJ; Offord, KP; Riggs, BL; Tsai, KS; Wahner, HW, 1987
)
0.27
" Even with the high serum levels of vitamin D metabolites, her intestinal 47Ca absorption rate remained in the lower normal range and urinary calcium excretion was decidedly low."( An unusual form of vitamin D-dependent rickets in a child: alopecia and marked end-organ hyposensitivity to biologically active vitamin D.
Cho, H; Kumagai, M; Matsuo, N; Orimo, H; Shiraki, M; Suda, T; Tsuchiya, Y; Yasaka, A, 1980
)
0.26
" The results demonstrate that vitamin D2 is well absorbed and hydroxylated in the 25 position by premature infants free of associated disease, and that a supplementation of 500 IU per day in addition to breast milk and a regular vitamin D fortified formula is adequate to rapidly establish 25-hydroxyvitamin D levels within the normal adult range."( Vitamin D nutritional status of premature infants supplemented with 500 IU vitamin D2 per day.
Aarskog, D; Aksnes, L; Finne, PH; Markestad, T, 1983
)
0.27
" Nonesterified vitamin D2 is well absorbed both in very young and older infants, although absorption efficiency increases with age, perhaps due to increased bile acid secretion."( Effect of age on the intestinal absorption of vitamin D3-palmitate and nonesterified vitamin D2 in the term human infant.
Guy, DG; Hansen, JW; Hollis, BW; Lowery, JW; Pittard, WB, 1996
)
0.29
"The bioavailability of vitamin D from mushrooms in humans is unknown."( Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay.
Lamberg-Allardt, CJ; Mattila, PH; Outila, TA; Piironen, VI, 1999
)
0.3
"We investigated the bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) using the increase in serum 25-hydroxyvitamin D concentrations as a measure of vitamin D bioavailability."( Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay.
Lamberg-Allardt, CJ; Mattila, PH; Outila, TA; Piironen, VI, 1999
)
0.3
"We showed for the first time that ergocalciferol was well absorbed from lyophilized and homogenized mushrooms in humans and that vitamin D bioavailability can be studied in humans with such an experimental protocol."( Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay.
Lamberg-Allardt, CJ; Mattila, PH; Outila, TA; Piironen, VI, 1999
)
0.3
"Obesity-associated vitamin D insufficiency is likely due to the decreased bioavailability of vitamin D(3) from cutaneous and dietary sources because of its deposition in body fat compartments."( Decreased bioavailability of vitamin D in obesity.
Chen, TC; Holick, MF; Lu, Z; Matsuoka, LY; Wortsman, J, 2000
)
0.31
" dose given the lower bioavailability of oral D hormones."( A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.
Elangovan, L; Mazess, RB, 2003
)
0.32
"We conducted 2 studies to determine the effect of vitamin D-fortified cheese on vitamin D status and the bioavailability of vitamin D in cheese."( Bioavailability of vitamin D from fortified process cheese and effects on vitamin D status in the elderly.
Hogie-Lorenzen, T; Hollis, BW; Johnson, JL; Mistry, VV; Specker, BL; Vukovich, MD, 2005
)
0.33
" Having previously optimized a method for the conversion of ergosterol in mushrooms to vitamin D2, this paper examines the vitamin D-enriched mushrooms (Lentinula edodes) for their bioavailability of the vitamin, using an animal model."( Bioavailability of vitamin D2 from irradiated mushrooms: an in vivo study.
Barlow, PJ; Jasinghe, VJ; Perera, CO, 2005
)
0.33
"A method has been optimized for the conversion of ergosterol in mushrooms to vitamin D2, and the vitamin D-enriched mushrooms have been tested for bioavailability of vitamin D2 using a rat model."( Vitamin D2 from irradiated mushrooms significantly increases femur bone mineral density in rats.
Barlow, PJ; Jasinghe, VJ; Perera, CO, 2006
)
0.33
" The present study evaluated the effects UV-C irradiation on vitamin D2 formation and its bioavailability in rats."( Vitamin D2 formation and bioavailability from Agaricus bisporus button mushrooms treated with ultraviolet irradiation.
Cho, KY; Jeong, SC; Koyyalamudi, SR; Pang, G; Song, CH, 2009
)
0.35
"The objective was to compare the bioavailability of vitamin D(2) and vitamin D(3) from orange juice with that from vitamin D(2) and vitamin D(3) supplements."( Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults.
Ameri, A; Biancuzzo, RM; Bibuld, D; Cai, MH; Chen, TC; Holick, MF; Klein, EK; Reitz, R; Salameh, W; Winter, MR; Young, A, 2010
)
0.36
" We assessed the bioavailability and efficacy of vitamin D in an 8 week dose-response study of bread made with vitamin D2-rich yeast compared to vitamin D3 in growing, vitamin D-deficient rats."( Bioavailability and efficacy of vitamin D2 from UV-irradiated yeast in growing, vitamin D-deficient rats.
Fleet, JC; Gordon, DT; Hohman, EE; Lachcik, PJ; Martin, BR; Weaver, CM, 2011
)
0.37
" Our objective was to investigate the bioavailability of vitamin D(2) from vitamin D(2)-enhanced mushrooms by UV-B in humans, and comparing it with a vitamin D(2) supplement."( Bioavailability of vitamin D₂ from UV-B-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial.
Bertz, H; Biesalski, HK; Ihorst, G; Singler, F; Urbain, P, 2011
)
0.37
"We are the first to demonstrate in humans that the bioavailability of vitamin D(2) from vitamin D(2)-enhanced button mushrooms via UV-B irradiation was effective in improving vitamin D status and not different to a vitamin D(2) supplement."( Bioavailability of vitamin D₂ from UV-B-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial.
Bertz, H; Biesalski, HK; Ihorst, G; Singler, F; Urbain, P, 2011
)
0.37
" The bioavailability of vitamin D during malnutrition is unknown."( Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa.
Brown, JN; Divasta, AD; Feldman, HA; Giancaterino, C; Gordon, CM; Holick, MF, 2011
)
0.37
"Despite severe malnutrition, young women with AN had a similar bioavailability of oral ergocalciferol as the healthy-weighted controls."( Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa.
Brown, JN; Divasta, AD; Feldman, HA; Giancaterino, C; Gordon, CM; Holick, MF, 2011
)
0.37
"75 L/h and bioavailability of 75."( Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
Awni, WM; Garimella, TS; Klein, CE; Lichtenberger, O; Noertersheuser, PA; Palaparthy, R; Pradhan, RS; Williams, LA, 2012
)
0.38
" Bioavailability was determined from changes in circulating levels of 25-hydroxyvitamin D [25(OH)D] and parathyroid hormone (PTH)."( Vitamin D2 from light-exposed edible mushrooms is safe, bioavailable and effectively supports bone growth in rats.
Babu, US; Calvo, MS; Dreher, M; Garthoff, LH; Hill, G; Nagaraja, S; Woods, TO, 2013
)
0.39
"We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D₂) or D₃."( Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis.
Carlucci, L; Cipriani, C; McMahon, DJ; Minisola, S; Nieddu, L; Pepe, J; Piemonte, S; Romagnoli, E; Russo, S; Singh, R, 2013
)
0.39
" UVB-exposed mushrooms synthesize vitD₂ but knowledge of bioavailability and function in immune response is lacking."( Vitamin D₂ from UVB light exposed mushrooms modulates immune response to LPS in rats.
Babu, US; Balan, KV; Calvo, MS; Garthoff, LH, 2014
)
0.4
"The objective of the present investigation was to determine bioavailability of calcium and vitamin D₂ from milk fortified with either calcium or vitamin D₂ alone or when both were used for preparation of multiple micronutrient fortified milk and also to study its interaction with iron and zinc bioavailability."( Bioavailability of vitamin D₂ and calcium from fortified milk.
Arora, S; Kapila, S; Kaushik, R; Sachdeva, B; Wadhwa, BK, 2014
)
0.4
" The main conclusions are: (i) ergocalciferol (vitamin D2), the form mostly used in supplements and fortified foods, is apparently absorbed with similar efficiency to cholecalciferol (vitamin D3, the main dietary form), (ii) 25-hydroxyvitamin D (25OHD), the metabolite produced in the liver, and which can be found in foods, is better absorbed than the nonhydroxy vitamin D forms cholecalciferol and ergocalciferol, (iii) the amount of fat with which vitamin D is ingested does not seem to significantly modify the bioavailability of vitamin D3, (iv) the food matrix has apparently little effect on vitamin D bioavailability, (v) sucrose polyesters (Olestra) and tetrahydrolipstatin (orlistat) probably diminish vitamin D absorption, and (vi) there is apparently no effect of aging on vitamin D absorption efficiency."( Vitamin D bioavailability: state of the art.
Borel, P; Caillaud, D; Cano, NJ, 2015
)
0.42
" We investigated the bioavailability of D2 from UV-irradiated yeast present in bread in an 8-week randomised-controlled trial in healthy 20-37-year-old women (n 33) in Helsinki (60°N) during winter (February-April) 2014."( Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women.
Cashman, KD; Erkkola, M; Itkonen, ST; Jakobsen, J; Lamberg-Allardt, C; Saaristo, P; Saarnio, EM; Skaffari, E, 2016
)
0.43
" Recent studies in humans focused on the bioavailability of vitamin D2 from mushrooms."( Vitamins D and D2 in Cultivated Mushrooms under Ultraviolet Irradiation and Their Bioavailability in Humans: A Mini-Review.
Cheung, PCK; Leung, MF, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Plasma-25-OHD was a power function of dosage with both compounds."( Comparison of oral 25-hydroxycholecalciferol, vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D.
Haddad, JG; Stamp, TC; Twigg, CA, 1977
)
0.26
" In addition considering that a lower dosage is required of 25OHD3 compared to vit."( [Behavior of serum 25-hydroxycholecalciferol in humans after administration of vitamin D and 25-OHD3].
Bianchi, AR; Bianchini, G; Casciani, CU; Coen, G; Gallucci, G; Lucentini, G; Matteucci, MC; Picca, S; Taccone Gallucci, M, 1979
)
0.26
" In rats fed by the diet optimal for the stimulation of C-cells division (11 rats, 2000 MU as a daily dosage of vitamin D2) within the interval from 1 to 10 days increased mitotic activity of the follicular cells was found from the 3rd day, while that of C-cells only as late as the 9th-10th day."( [The mitotic activity of the follicular and parafollicular (C) cells in the thyroid of rats with hypercalcemia].
Pavlov, AV, 1992
)
0.28
"In 23 patients with hypoparathyroidism or pseudohypoparathyroidism treated with vitamin D, and in whom the dosage was adjusted downward or upward in response to hypercalcemia or hypocalcemia respectively, assays of serum 25-hydroxyvitamin D (25-OHD) were carried out in addition to the usual serum calcium assays."( The value of serum 25-hydroxyvitamin D measurements in hypoparathyroid and pseudohypoparathyroid patients treated with calciferol.
Burns, J; Paterson, CR, 1986
)
0.27
" The experiments on the transfer of 3H-D3 and 3H-25-OH-D3 perorally dosed to lactating rats into suckling pups through their milk also supported the above conclusion."( Lack of evidence for existence of vitamin D and 25-hydroxyvitamin D sulfates in human breast and cow's milk.
Hirao, N; Kobayashi, T; Kodama, S; Kuroda, E; Matsuo, T; Nakajima, K; Nakamichi, Y; Nakao, H; Okano, T, 1986
)
0.27
" The serum 25(OH)D2 was maintained at normal concentrations for most of the year in the once-a-year dosage group but at the end of 12 months only 60% were fully protected."( Vitamin D prophylaxis in the elderly: a simple effective method suitable for large populations.
Davies, M; Hann, JT; Mawer, EB; Stephens, WP; Taylor, JL, 1985
)
0.27
" Renal calcification were more pronounced after dosing with 1 alpha OHD3 than after treatment with 1 alpha OHD2."( Effects of vitamin D. A comparison of 1 alpha OHD2 and 1 alpha OHD3 in rats.
Sjödén, G, 1985
)
0.27
"5 mg/day of prednisolone on the amount of calcium deposited in the kidney of rats dosed with either 500 ng/d or 2000 ng/day of 1-alpha OHD2 or 1-alpha OHD3."( The effect of prednisolone on kidney calcification in vitamin D-treated rats.
Lindgren, U; Sjöden, G, 1985
)
0.27
" 3 and 4) given the respective vitamins at a daily dosage of 33,000 IU/kg of initial (day 0) body weight for 30 days."( Acute vitamin D3 toxicosis in horses: case reports and experimental studies of the comparative toxicity of vitamins D2 and D3.
Harrington, DD; Page, EH, 1983
)
0.27
" A dose-response inhibition of the response of serum 25-OHD to vitamin D by 1,25(OH)2D3 was demonstrated in two of the normal subjects."( Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man.
Bell, NH; Shaw, S; Turner, RT, 1984
)
0.27
" The doses of phenobarbitone and phenytoin were each inversely related to plasma 25-(OH)D concentration, but anticonvulsant drug dosage did not correlate with the magnitude of the decline of plasma 25-(OH)D concentration in winter (November-February)."( Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D.
Barnes, JL; Barnes, ND; Davie, MW; Emberson, CE; Heeley, AF; Lawson, DE; Roberts, GE, 1983
)
0.27
" From the results obtained it is concluded that (1) patients with CRF differ from normal subjects in handling of high doses of vitamin D and (2) high dosage treatment with vitamin D may prevent hypocalcemia in patients with CRF in spite of high proteinuria."( Serum 25-hydroxyvitamin D in patients with chronic renal failure on long-term treatment with high doses of vitamin D2.
Fröhling, PT; Kaschube, I; Kokot, F; Kuska, J; Pietrek, J; Vetter, K, 1980
)
0.26
"The biliary metabolites of vitamin D2 obtained from chickens dosed with 3H-labeled vitamin D2 were investigated."( Isolation and identification of 25-hydroxyvitamin D2 25-glucuronide: a biliary metabolite of vitamin D2 in the chick.
DeLuca, HF; LeVan, LW; Schnoes, HK, 1981
)
0.26
" Since steroid therapy is often mandatory the main therapeutic implications are that the more severely affected child often needs vitamin D supplementation in "physiological" dosage, and that early mobilisation and reduction of steroid dosage should be constant aims."( Bone rarefaction and crush fractures in juvenile chronic arthritis.
Ansell, BM; Elsasser, U; Hesp, R; Reeve, J; Thurnham, DI; Wilkins, B, 1982
)
0.26
" We studied vitamin D transport from the skin in seven healthy volunteers who received whole body irradiation with 27 mJ/cm2 dosage of ultraviolet B light (290-320 nm)."( Human plasma transport of vitamin D after its endogenous synthesis.
Haddad, JG; Hollis, BW; Hu, YZ; Matsuoka, LY; Wortsman, J, 1993
)
0.29
" No correlation was found between the dosage of phosphate supplements or urinary phosphate excretion and urinary oxalate excretion, in either group of patients."( Hyperoxaluria is not a cause of nephrocalcinosis in phosphate-treated patients with hereditary hypophosphatemic rickets.
Blonder, J; Gabizon, D; Manor, H; Maor, J; Sela, BA; Shaked, U; Strauss, S; Tieder, M, 1993
)
0.29
"The characterization of vitamin D2 3-glucuronide, 25-hydroxyvitamin D2 3-glucuronide and 25-hydroxyvitamin D2 25-glucuronide, biliary metabolites obtained from rats dosed with vitamin D2 and 25-hydroxyvitamin D2 per os, was carried out using HPLC-atmospheric pressure chemical ionization (APCI)-MS."( Characterization of monoglucuronides of vitamin D2 and 25-hydroxyvitamin D2 in rat bile using high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
Mitamura, K; Nakatani, I; Shimada, K, 1997
)
0.3
" Dose-response curves generated after oral and subcutaneous administration of 1 alpha,24(OH)2D2, calcitriol, and calcipotriol to normal rats indicated that 1 alpha,24(OH)2D2 increases serum and urine calcium to a much lesser extent than calcitriol, and to a slightly greater extent than calcipotriol."( Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol.
Bishop, CW; Knutson, JC; LeVan, LW; Valliere, CR, 1997
)
0.3
" The study end point for efficacy was at least a 30% reduction from maximum baseline in iPTH level for 75% of the patients receiving paricalcitol per dosing group."( Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Arruda, J; Delmez, J; Goldblat, MV; Keshav, G; Lau, A; Lindberg, JS; Llach, F; Sadler, R; Slatopolsky, E, 1998
)
0.3
" The rats were dosed orally with each sterol for 7 days at a rate of 1 ng/g body weight/day."( Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat.
Bishop, C; Horst, R; Knutson, J; Koszewski, N; Prapong, S; Reinhardt, T, 2000
)
0.31
" Time-course and dose-response studies on 1,25-(OH)(2)D(3) and 19-nor-1,25-(OH)(2)D(2) induction of the marker of bone formation, osteocalcin, showed overlapping curves."( Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells.
Dusso, AS; Finch, JL; Pavlopoulos, T; Slatopolsky, EA, 2001
)
0.31
" Subsequent dosing was based on iPTH, calcium, and phosphorus determinations."( Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach, F; Yudd, M, 2001
)
0.31
" We conducted a double-blind, double-dummy, randomized, 12-week, multicenter trial to compare the incidence of hypercalcemia (single occurrence) between two dosing regimens: one regimen based on baseline intact parathyroid hormone (iPTH; PTH/80) level, and the other regimen based on patient body weight (0."( Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.
Amdahl, M; González, E; Lindberg, JS; Llach, F; Malhotra, K; Martin, KJ; Taccetta, C, 2001
)
0.31
"Mice were randomized into treatment and control groups for 5-week toxicity and dose-response studies."( Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.
Albert, DM; Bryar, PJ; Darjatmoko, SR; Grostern, RJ; Lindstrom, MJ; Lissauer, BJ; Lokken, JM; Strugnell, SA; Zimbric, ML, 2002
)
0.31
"2 microg/d were selected on the basis of toxicity studies for the dose-response trial."( Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.
Albert, DM; Bryar, PJ; Darjatmoko, SR; Grostern, RJ; Lindstrom, MJ; Lissauer, BJ; Lokken, JM; Strugnell, SA; Zimbric, ML, 2002
)
0.31
" More aggressive paricalcitol dosing and close patient follow up was shown to be effective in the management of SHPT."( Severe secondary hyperparathyroidism.
Chmielewski, C; Foerster, D, 2001
)
0.31
" Dosing was 5X/week for five weeks."( Vitamin D analogs, a new treatment for retinoblastoma: The first Ellsworth Lecture.
Albert, DM; Audo, I; Gamm, DM; Lindstrom, MJ; Nickells, RW; Schlamp, CL; Zimbric, ML, 2002
)
0.31
"Treatment of hyperparathyroidism includes the use of 1,25-dihydroxy-vitamin D3 (1,25D3) to suppress parathyroid hormone (PTH), but dosing of 1,25D3 is limited by the development of hypercalcemia and a high calcium x phosphorus (Ca x P) product because of gut absorption of calcium and phosphorus and enhanced bone resorption."( Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
Ahya, SN; Coyne, DW; Giles, K; Grieff, M; Norwood, K; Slatopolsky, E, 2002
)
0.31
" Five different methods for dosing phosphate binders were determined."( The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.
Martin, CJ; Reams, SM, 2003
)
0.32
" and oral dosing was found in 10 of the 15 articles in which efficacy was assessed."( A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.
Elangovan, L; Mazess, RB, 2003
)
0.32
"The results of this study demonstrate that a majority of adults with CF have serum 25-OHD levels below 30 ng/ml, and the currently recommended ergocalciferol repletion regimen often does not fully correct vitamin D deficiency and may need to be revised to include even higher dosing of ergocalciferol."( Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis.
Boyle, MP; Davis, ME; Lechtzin, N; Noschese, ML; Stenner, SE; Watts, SL, 2005
)
0.33
" Less frequent dosing would be more convenient, require less nursing time, and be an option in other dialysis modalities."( Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Cheng, SC; Coyne, DW; Staniforth, ME, 2005
)
0.33
"Once-weekly dosing of paricalcitol is an effective option in treatment of secondary hyperparathyroidism."( Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Cheng, SC; Coyne, DW; Staniforth, ME, 2005
)
0.33
"Combined dosing of pamidronate and 1,24(OH)2D2 may have therapeutic value for the treatment of multiple myeloma, prostate and breast cancers."( Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells.
Knutson, JC; Strugnell, SA; Wigington, DP,
)
0.13
"In patients on a maintenance dose of paricalcitol, dosing doxercalciferol at 55-60% of the paricalcitol dose results in comparable inhibition of PTH."( Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Ghantous, W; Roberts, L; Schinleber, P; Sprague, SM; Zisman, AL,
)
0.13
" The capsule form of paricalcitol was developed to provide a convenient dosage form for patients with stages 3 and 4 CKD."( Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Abboud, H; Acharya, M; Andress, DL; Batlle, D; Coyne, D; Fadem, S; Levine, B; Qiu, P; Rosansky, S; Sprague, SM; Williams, L, 2006
)
0.33
" Two studies used a thrice-weekly dosing regimen and 1 study used a once-daily dosing regimen for 24 weeks."( Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
Abboud, H; Acharya, M; Andress, DL; Batlle, D; Coyne, D; Fadem, S; Levine, B; Qiu, P; Rosansky, S; Sprague, SM; Williams, L, 2006
)
0.33
"Intermittent dosing of calcitriol for secondary hyperparathyroidism (SHPT) has been associated with greater parathyroid hormone (PTH) reduction with fewer calcemic and phosphatemic effects than daily (QD) dosing."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.33
"Secondary analyses of three randomized, double-blind, placebo-controlled multicenter studies in stage 3 and 4 chronic kidney disease (CKD) patients with SHPT were performed to compare three times per week (TIW) with QD dosing of paricalcitol."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.33
"Pharmacokinetics revealed similar steady state paricalcitol exposure between dosing regimens."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.33
"QD dosing of paricalcitol capsules is as efficacious as TIW dosing in achieving the primary end point (2 consecutive > or = 30% reductions in PTH) in stage 3 and 4 CKD patients with SHPT."( A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA, 2006
)
0.33
"Treatment of secondary hyperparathyroidism (SHPT) includes use of calcitriol (1,25D(3)) to suppress parathyroid hormone (PTH), but dosing of 1,25D(3) is limited by the development of hypercalcemia and a high calcium x phosphorus (Ca x P) product due to gut absorption of calcium and phosphorus as well as enhanced bone resorption."( Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Ahya, SN; Coyne, DW; Giles, K; Joist, HE; Norwood, K; Slatopolsky, E, 2006
)
0.33
" Data suggest that dosing should be gauged according to degree of SHPT."( Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients.
Abitbol, CL; Chandar, J; Nwobi, O; Seeherunvong, W; Strauss, J; Zilleruelo, G, 2006
)
0.33
" Uremic patients, however, suffer from severe deprivation of biological vitamin D effects, that puts them in need of highly dosed vitamin D in order to both ameliorate their bone status and to preserve their general and cardiovascular health."( Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both?
Cannella, G; Messa, P,
)
0.13
" The drug is available in both oral and intravenous dosage forms."( Doxercalciferol treatment of secondary hyperparathyroidism.
Albertson, GL; Dennis, VC, 2006
)
0.33
" Fifty-two patients with stage 3 or stage 4 CKD with vitamin D deficiency and elevated PTH concentrations received ergocalciferol dosed per a modified K/DOQI guidelines protocol and adjusted every 3 months."( Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Ho, LT; Hristova, M; Sprague, SM; Zisman, AL, 2007
)
0.34
" The appropriate dosing regimen for improving vitamin D status in this population is not known."( Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women.
Afandi, BO; Benedict, S; Dawodu, A; Nagelkerke, N; Saadi, HF; Zayed, R, 2007
)
0.34
" Monthly dosing appears to be a safe and effective alternative to daily dosing."( Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women.
Afandi, BO; Benedict, S; Dawodu, A; Nagelkerke, N; Saadi, HF; Zayed, R, 2007
)
0.34
" Other practical issues, including who should receive vitamin D replacement, what form of vitamin D should be used, and what dosage is required to prevent falls, are discussed."( Vitamin D supplementation to prevent falls in the elderly: evidence and practical considerations.
Fosnight, SM; Hazelett, SE; Zafirau, WJ, 2008
)
0.35
" It was hypothesized that the ratio of the administered paricalcitol dosage to serum PTH level discloses better the underlying dosage-survival association."( Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Greenland, S; Kalantar-Zadeh, K; Kopple, JD; Kovesdy, CP; McAllister, CJ; Shinaberger, CS; van Wyck, D, 2008
)
0.35
"Higher weekly paricalcitol dosage per each unit of serum PTH seems to have an incremental association with greater survival in MHD patients."( Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Greenland, S; Kalantar-Zadeh, K; Kopple, JD; Kovesdy, CP; McAllister, CJ; Shinaberger, CS; van Wyck, D, 2008
)
0.35
" Prospective studies are required to determine appropriate dosing regimen to achieve optimal levels in the majority of MS patients and to ascertain the safety, immunological response, and ultimately the clinical efficacy of vitamin D replacement therapy."( Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
Baynes, M; Calabresi, PA; Cettomai, D; Greenberg, BM; Harrison, D; Hiremath, GS; Kerr, D; Newsome, S; Ratchford, JN, 2009
)
0.35
" The results of this study demonstrate that very high dosing of vitamin D using oral ergocalciferol over a 14 day period is an effective strategy in achieving therapeutic levels of 25-OH vitamin D in children and young adults with CF."( Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis.
Boas, SR; Hageman, JR; Ho, LT; Liveris, M, 2009
)
0.35
" There was a reduction in the dosage and in the number of patients who were treated with paricalcitol and sevelamer."( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010
)
0.36
" It allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction."( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010
)
0.36
" Future studies should examine the effects of higher or more frequent dosing of ergocalciferol on these clinical endpoints."( Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?
Abdellatif, A; Cadena, A; Gelfond, J; Hamdan, Z; Ingle, J; Kasinath, B; Lin, FY; Qunibi, WY; Sankar, S, 2010
)
0.36
" While many older patients can be expected to have vitamin D deficiencies, pharmacists should be aware of appropriate replenishment therapies and correct dosing of different vitamin D products."( Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity.
Cappuzzo, KA; Carlton, S; Clopton, D, 2010
)
0.36
" Dose-response studies of the comedolytic analogs showed that an increase in epidermal thickness was achieved at a lower dose than that needed to induce comedolysis."( Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse.
Ahrens, JM; Clagett-Dame, M; DeLuca, HF; Nieves, NJ; Plum, LA, 2010
)
0.36
" Calciferols were dosed at 50,000 IU/wk for 12 wk."( Vitamin D(3) is more potent than vitamin D(2) in humans.
Armas, LA; Grote, J; Heaney, RP; Horst, RL; Recker, RR, 2011
)
0.37
"The aim of the study was to evaluate the effect of daily and once monthly dosing of D(2) or D(3) on circulating 25(OH)D and serum and urinary calcium."( Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults.
Binkley, N; Drezner, MK; Engelke, J; Gangnon, R; Gemar, D; Krueger, D; Ramamurthy, R, 2011
)
0.37
" One year of D(2) or D(3) dosing (1,600 IU daily or 50,000 IU monthly) does not produce toxicity, and 25(OH)D levels of less than 30 ng/ml persist in approximately 20% of individuals."( Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults.
Binkley, N; Drezner, MK; Engelke, J; Gangnon, R; Gemar, D; Krueger, D; Ramamurthy, R, 2011
)
0.37
" We assessed the bioavailability and efficacy of vitamin D in an 8 week dose-response study of bread made with vitamin D2-rich yeast compared to vitamin D3 in growing, vitamin D-deficient rats."( Bioavailability and efficacy of vitamin D2 from UV-irradiated yeast in growing, vitamin D-deficient rats.
Fleet, JC; Gordon, DT; Hohman, EE; Lachcik, PJ; Martin, BR; Weaver, CM, 2011
)
0.37
" The validated method was used for paricalcitol determination in a formal stability study of its pharmaceutical dosage form in preloaded syringes."( Validated stability-indicating HPLC method for paricalcitol in pharmaceutical dosage form according to ICH guidelines: application to stability studies.
Cabeza, J; Capitán-Vallvey, LF; Navas, N; Ortega, R; Salmerón, A,
)
0.13
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Vitamin D dosing for patients suffering from malnutrition may not differ from that for normal-weighted adolescents."( Bioavailability of vitamin D in malnourished adolescents with anorexia nervosa.
Brown, JN; Divasta, AD; Feldman, HA; Giancaterino, C; Gordon, CM; Holick, MF, 2011
)
0.37
" As more and more people use vitamin D supplements, it is important to recognize that, while rare, hypervitaminosis D is a possibility and dosage conversion of vitamin D units can result in errors."( Hypervitaminosis D associated with a vitamin D dispensing error.
Hronek, BW; Jacobsen, RB; Schilling, ML; Schmidt, GA, 2011
)
0.37
" In addition, health care providers should understand dosage conversion regarding vitamin D and electronic prescribing and dispensing software should be designed to detect such errors."( Hypervitaminosis D associated with a vitamin D dispensing error.
Hronek, BW; Jacobsen, RB; Schilling, ML; Schmidt, GA, 2011
)
0.37
" Cumulative dosing may be more important than frequency of dosing (strength of recommendation [SOR]: C, inconsistent results from randomized controlled trials [RCTs] of disease-oriented outcomes)."( Clinical inquiries. Which regimen treats vitamin D deficiency most effectively?
Germann, A; Osborn, J; St Anna, L, 2011
)
0.37
" Even though doxercalciferol usage and dosing was similar between groups, plasma sVCAM-1, sICAM-1 and P-selectin concentrations were lower among ergocalciferol treated patients."( Nutritional vitamin D supplementation in haemodialysis: A potential vascular benefit?
Assimon, MM; El-Fawal, HA; Mason, DL; Salenger, PV, 2012
)
0.38
" Nevertheless, the current evidence suggests that regular dosing with oral cholecalciferol (e."( Prevention and treatment of vitamin D deficiency.
Cheetham, TD; Pearce, SH; Sinha, A, 2013
)
0.39
"04) g/24 h with 6 patients not receiving any anti-RAS and 42 treated with a single agent, at low dosage in most cases."( Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.
Conte, G; De Nicola, L; Gorini, A; Minutolo, R; Russo, D, 2012
)
0.38
" Paricalcitol was dosed according to parathyroid hormone (PTH): 1mg/day for patients with PTH < 500 pg/ml, and 2mg/day for those with higher PTH levels."( Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Coronel-Aguilar, D; Fernández-Viña, A; González-Díaz, I; Núñez-Moral, M; Peláez-Requejo, B; Quintana-Fernández, A; Rodríguez-Suárez, C; Sánchez-Álvarez, JE, 2013
)
0.39
" The ESA dosage was recorded monthly."( Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.
Boonyapapong, P; Rianthavorn, P, 2013
)
0.39
"Optimal dosing regimens for 25-OH vitamin D (VitD) deficiency are unknown in hemodialysis (HD) patients."( Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen.
Akkina, S; Arruda, J; Gilmartin, C; Porter, A; Srisakul, U, 2013
)
0.39
"004), there were no significant difference in bone/mineral or anemia parameters including dosing of darbepoetin."( Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen.
Akkina, S; Arruda, J; Gilmartin, C; Porter, A; Srisakul, U, 2013
)
0.39
" The dosing of study drugs and phosphate binders in the IMPACT study may not reflect actual practice, and patients were followed for 28 weeks, while the treatment of SHPT is long-term."( Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Ketteler, M; Khan, SS; Marshall, TS; Schumock, GT; Sharma, A, 2013
)
0.39
" This may be due to medical professionals being less aware of the multitude of factors that can influence treatment when dosing a product."( Vitamin D therapy and related metabolomics: is the calciferol dose and form the only requirements for successful clinical therapeutics?
Braithwaite, MC; Choonara, YE; Kumar, P; Pillay, V; Tomar, LK; Tyagi, C, 2013
)
0.39
" This study examined efficacy and safety of two dosing regimens of selective vitamin D receptor activator paricalcitol."( Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
Amdahl, M; Chen, N; Huang, Z; Jiang, G; Khan, S; Li, X; Lin, H; Liu, L; Qian, J; Wang, M; Xing, C; Yan, Y; Yu, X; Zuo, L, 2014
)
0.4
"Both EU and US PI paricalcitol dosing strategies effectively reduced iPTH levels in Chinese subjects with SHPT, with minimal impact on Ca and P levels."( Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
Amdahl, M; Chen, N; Huang, Z; Jiang, G; Khan, S; Li, X; Lin, H; Liu, L; Qian, J; Wang, M; Xing, C; Yan, Y; Yu, X; Zuo, L, 2014
)
0.4
" Costs were estimated by examining the dosage of the study drug (paricalcitol or cinacalcet) and phosphate binders used by each participant during the trial."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.4
"On the basis of dosing and effectiveness data from US patients in the IMPACT SHPT study, we found that a regimen of intravenous paricalcitol was more cost effective than cinacalcet plus low-dose vitamin D in the management of iPTH in patients with SHPT requiring haemodialysis."( Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Johns, B; Khan, SS; Marshall, TS; Sharma, A, 2014
)
0.4
" We therefore aimed to investigate the importance of body weight for the dose-response relation in circulating 25OHD."( Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review.
Börgermann, J; Ernst, JB; Gummert, JF; Zittermann, A, 2014
)
0.4
"05 for both dosing strata) at Weeks 8, 16 and 28."( Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A, 2014
)
0.4
" Clinicians would have informed of choosing the dosing regimen of ergocalciferol in metabolic syndrome patients."( Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome.
Krittiyanunt, S; Phetkrajaysang, N; Sansanayudh, N; Wongwiwatthananukit, S, 2014
)
0.4
"Controversy exists on which vitamin D (D2 or D3) and which dosage scheme is the best to obtain and maintain adequate 25 OH D levels in dialysis patients safely."( Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: a pilot trial.
Bevione, P; Bravo, M; Canalis, M; Curcelegui, M; Del Valle, E; Fradinger, E; Gottlieb, E; Marini, A; Negri, AL; Peri, P; Puddu, M; Rosa Diez, G; Ryba, J; Sintado, L, 2015
)
0.42
" The dosage of the vitamin D was normal for 28% of patients (n=46)."( [Study of vitamin D supplementation in people over 65 years in primary care].
Berrut, G; Breysse, C; Guillot, P, 2015
)
0.42
"There are wide variations in recommended dosing for vitamin D repletion."( Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients.
Aterrado, S; Kanehira-Mar, S; Meier, J; Ono, G; Swislocki, A, 2015
)
0.42
" Ergocalciferol and cholecalciferol groups were separately organized into quartiles to identify dosing ranges that had the most impact on changes in 25(OH)D laboratory values."( Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients.
Aterrado, S; Kanehira-Mar, S; Meier, J; Ono, G; Swislocki, A, 2015
)
0.42
" Most regimens in current use are based on daily dosing, which may raise concerns of dosage inadequacy and suboptimal patient compliance."( Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency.
Aiedeh, KM; Hadidi, KA; Melhem, SJ,
)
0.13
" The shortened dosing interval over 10 consecutive days might result in higher compliance."( Effects of a 10-day course of a high dose calciferol versus a single mega dose of ergocalciferol in correcting vitamin D deficiency.
Aiedeh, KM; Hadidi, KA; Melhem, SJ,
)
0.13
"The aim of this study was to evaluate the dose-response relationship between ergocalciferol therapy and serum 25-hydroxyvitamin D concentrations in enterally fed, critically ill patients with traumatic injuries."( Dose-response effect of ergocalciferol therapy on serum 25-hydroxyvitamin D concentration during critical illness.
Berry, SC; Brown, RO; Dickerson, RN; Maish, GO; Minard, G; Swanson, JM; Ziebarth, JD, 2015
)
0.42
"Sixty-five patients (16, 18, and 31 per dosage group) were examined."( Dose-response effect of ergocalciferol therapy on serum 25-hydroxyvitamin D concentration during critical illness.
Berry, SC; Brown, RO; Dickerson, RN; Maish, GO; Minard, G; Swanson, JM; Ziebarth, JD, 2015
)
0.42
" The trend in increasing appearance of mild hypercalcemia for the highest dosage group is concerning."( Dose-response effect of ergocalciferol therapy on serum 25-hydroxyvitamin D concentration during critical illness.
Berry, SC; Brown, RO; Dickerson, RN; Maish, GO; Minard, G; Swanson, JM; Ziebarth, JD, 2015
)
0.42
" The patients were randomized into two groups, control group treated with ergocalciferol as recommended by K/DOQI guidelines, and treatment group treated with double dosage of ergocalciferol from the recommendation."( Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
Chaiprasert, A; Satirapoj, B; Supasyndh, O; Thimachai, P, 2015
)
0.42
"Vitamin D2 or ergocalciferol can replace vitamin D3, but its dosage must be a higher international unit: one unit of vitamin D3 is equal to 4 units ofvitamin D2."( Study of the Safe Dosage of Ergocalciferol.
Bunyaratavej, N, 2015
)
0.42
" However, no consistent differences between routes of administration, frequencies of dosing or vitamin D preparations were demonstrated."( Interventions for metabolic bone disease in children with chronic kidney disease.
Craig, JC; Hahn, D; Hodson, EM, 2015
)
0.42
" Pregnant women were enrolled at 27 wk of gestation and randomly assigned to the following 3 groups: a placebo group, a group who received one dosage of daily oral vitamin D3 (1000 IU), or a group who received 2 dosages of daily oral vitamin D3 (2000 IU)."( Vitamin D activity of breast milk in women randomly assigned to vitamin D3 supplementation during pregnancy.
Camargo, CA; Crane, J; Ekeroma, A; Grant, CC; Horst, R; Milne, T; Mitchell, EA; Rowden, J; Scragg, R; Stewart, AW; Wall, CR, 2016
)
0.43
" Then paricalcitol was administered intraperitoneally to isoproterenol-injected rats at a dosage of 200 ng three times a week for 3 weeks."( Paricalcitol Attenuates Cardiac Fibrosis and Expression of Endothelial Cell Transition Markers in Isoproterenol-Induced Cardiomyopathic Rats.
Cheng, PW; Hsiao, M; Lai, CC; Liou, JC; Liu, CP; Lu, PJ; Lu, WH; Sun, GC; Tseng, CJ, 2016
)
0.43
"To investigate the effects of Vitamin D Analogs, paricalcitol and alphacalcidol, on hemoglobin levels and erythropoietin-stimulating agents' dosage in hemodialysis patients with chronic renal failure."( EFFECTS OF VITAMIN D ANALOGS ON ERYTHROPOIESIS-STIMULATING AGENT DASAGE AND SECONDARY ANEMIA IN HEMODIALYSIS PATIENTS.
Kaya, T; Nalbant, A; Sipahi, S; Varim, C; Yaylaci, S, 2016
)
0.43
" Until further safety data is available, bolus dosing or daily doses should not exceed 3,000 IU and serum levels of 25-hydroxyvitamin D should not exceed 40-45 ng/ml (equivalent to 100-112 nmol/l) in elderly individuals."( Vitamin D and falls - the dosage conundrum.
Gallagher, JC, 2016
)
0.43
" Serum PTH remained suppressed during the dosing period, but tended to rebound in the paricalcitol groups."( Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Chen, YW; Fukagawa, M; Kakuta, T; Kanai, G; Sawada, K; Wessale, JL; Wu-Wong, JR, 2017
)
0.46
" The optimal dosing regimen still needs to be determined for the average Crohn's disease patient."( Correction of vitamin D deficiency using sublingually administered vitamin D2 in a Crohn's disease patient with mal-absorption and a new ileostomy.
Heaney, R; McCullough, P, 2017
)
0.46
" Model simulations compared 25OHD exposures, following repeated D2 and D3 oral administration across typical dosing and baseline ranges."( Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics.
Gastonguay, MR; Ocampo-Pelland, AS; Riggs, MM, 2017
)
0.46
" Improvement in PCS was greater in patients whose calcitriol dosage was reduced and duration of disease was shorter."( Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.
Almonte, MG; Bilezikian, JP; Cusano, NE; Majeed, R; Omeragic, B; Rubin, MR; Tabacco, G; Tay, YD; Williams, J, 2019
)
0.51
" The conventional-group (N = 35) and the high-dose group (N = 35) were treated with ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol from the recommendation for 8 weeks, respectively."( Efficacy of high versus conventional dose of ergocalciferol supplementation on serum 25-hydroxyvitamin D and interleukin-6 levels among hemodialysis patients with vitamin D deficiency: A multicenter, randomized, controlled study.
Nata, N; Satirapoj, B; Siricheepchaiyan, W; Supasyndh, O, 2022
)
0.72
" Intact parathyroid hormone (iPTH), total serum calcium (Ca), phosphate (P), dosage of intravenous (IV) paricalcitol (Zemplar®) were analyzed and discussed via retrospective analysis of the database during the treatment."( Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis.
Jiang, G; Wang, N; Xie, Y, 2022
)
0.72
" The intention of this review article is to provide guidance on the recommended dosage regimen as a prophylactic measure during COVID-19 and its use as a supplement in general."( Vitamin D supplementation in a post-pandemic era: A narrative review.
Bopape, PG; Bronkhorst, E; Poka, M; Wagenaar, C, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (70 Product(s))

Product Categories

Product CategoryProducts
Other2
Beauty & Personal Care2
Professional Supplements1
Vitamins & Supplements22
Herbs, Botanicals & Homeopathy3
Pet Supplies1
Food & Beverages28
Active Lifestyle & Fitness7
Weight Management4

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Beauty Without Cruelty Nourishing Eye Gel -- 1 ozBeauty Without CrueltyBeauty & Personal CareAllantoin, Chamomile, Panthenol, Glycerin, Phenoxyethanol, Ergocalciferol2024-11-29 10:47:42
DaVinci Laboratories Cal-Mag Citrate Powder -- 5.78 ozDaVinci LaboratoriesProfessional SupplementsVitamin D22024-11-29 10:47:42
Deva Vegan Cal-Mag Plus -- 90 TabletsDevaVitamins & SupplementsVitamin C, Boron, calcium carbonate, citrate, citrate, Vitamin D2, Vitamin K2024-11-29 10:47:42
Deva Vegan Hair Nails and Skin -- 90 TabletsDevaVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, L-cysteine, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B3, PABA, Vitamin B5, Vitamin B6, Vitamin B2, Beta Sitosterol, Vitamin B1, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Supplement -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Betaine HCL, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Calcium Carbonate, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Tiny Tablets -- 90 TabletsDevaVitamins & SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin and Mineral Supplement Iron Free -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Prenatal One Daily Multivitamin and Mineral -- 90 Coated TabletsDevaVitamins & SupplementsChamomile, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Deva Vegan Vitamin D -- 2400 IU - 90 TabletsDevaVitamins & SupplementsVitamin D22024-11-29 10:47:42
Deva Vegan Vitamin D -- 800 IU - 90 TabletsDevaVitamins & SupplementsVitamin D22024-11-29 10:47:42
Earth Science A-D-E Creamy Cleanser -- 8 fl ozEarth ScienceBeauty & Personal Careglyceryl dilaurate, allantoin, ascorbic acid, tocopherol, tocopherol, glyceryl stearate, glycerin, lactic acid, phenoxyethanol, PEG-8 stearate, retinyl palmitate, ergocalciferol2024-11-29 10:47:42
Goli Nutrition Ashwagandha Gummies Mixed Berry -- 120 GummiesGoli NutritionHerbs, Botanicals & HomeopathyVitamin D22024-11-29 10:47:42
Goli Nutrition Ashwagandha Gummies Mixed Berry -- 60 GummiesGoli NutritionHerbs, Botanicals & HomeopathyVitamin D22024-11-29 10:47:42
Goli Nutrition Dreamy Sleep Gummies -- 60 GummiesGoli NutritionVitamins & SupplementsMelatonin, Vitamin D22024-11-29 10:47:42
Goli Nutrition Extra-Strength Sleep Gummies -- 50 GummiesGoli NutritionVitamins & SupplementsMelatonin, Vitamin D22024-11-29 10:47:42
Goli Nutrition Kids Complete MultiVitamin Vegan -- 80 GummiesGoli NutritionVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folate, Vitamin E, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K12024-11-29 10:47:42
Greens First Boost Dutch Chocolate -- 10.5 ozGreens FirstVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Magnesium Phosphate, Manganese, Molybdenum, Niacin, Vitamin B5, Phosphorus, Potassium Phosphate, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Greens First Boost French Vanilla -- 10.5 ozGreens FirstVitamins & SupplementsVitamin C, Biotin, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Magnesium Phosphate, Manganese, Molybdenum, Niacin, Vitamin B5, Phosphorus, Potassium Phosphate, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Halo Holistic Dry Dog Food Vegan Superfoods Plant-Based Recipe -- 3.5 lbsHaloPet Suppliesbiotin, d-calcium pantothenate, dicalcium phosphate, copper sulfate, iron sulfate, folic acid, calcium carbonate, potassium chloride, pyridoxine hydrochloride, vitamin A acetate, taurine, ergocalciferol, zinc sulfate2024-11-29 10:47:42
Human Beanz Multivitamin Jelly Beans Essential Vitamins Plus Zinc Berry Blast -- 120 Jelly BeansHuman BeanzVitamins & Supplementscitric acid, Vitamin C, Biotin, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Iodine, maltodextrin, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sodium citrate, Sugar, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Lifetime All One Rice Base Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Beta Carotene, Betaine HCl, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Potassium Iodide, Vitamin B6, Retinol Acetate, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lifetime Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Mason Natural Daily Multiple Vitamins With Iron -- 365 TabletsMason NaturalVitamins & SupplementsPABA, Vitamin C, Vitamin E, Folate, Vitamin E, Microcrystalline cellulose, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, stearic acid, Vitamin B1, titanium dioxide, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Mightylicious Cookies Vegan Gluten Free Chocolate Chip -- 6.5 ozMightyliciousFood & Beveragesbaking soda, cane sugar, vanilla, vitamin B12, vitamin D22024-11-29 10:47:42
Mightylicious Cookies Vegan Gluten Free Oatmeal Coconut -- 6.5 ozMightyliciousFood & Beveragesbaking soda, cane sugar, vanilla, vitamin B12, vitamin D22024-11-29 10:47:42
Milkadamia Macadamia Milk Original -- 32 fl ozMilkadamiaFood & BeveragesVitamin C, vitamin A palmitate, Vitamin A, cane sugar, calcium phosphate, Vitamin B12, vitamin D22024-11-29 10:47:42
Milkadamia Macadamia Milk Unsweetened -- 32 fl ozMilkadamiaFood & BeveragesVitamin C, vitamin A palmitate, Vitamin A, calcium phosphate, Vitamin B12, vitamin D22024-11-29 10:47:42
MRM Veggie Meal Replacement Vanilla Bean -- 3 lbsMRMActive Lifestyle & FitnessAlanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Cysteine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glycine, Histidine, Iodine, Isoleucine, Leucine, Lysine, Methionine, Niacin, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Serine, Thiamin, Threonine, trehalose, Tryptophan, Tyrosine, Valine, Vitamin B6, Vitamin D22024-11-29 10:47:42
Naturade VeganSmart Protein & Greens Vanilla Crème -- 22.8 ozNaturadeWeight ManagementVitamin C, Biotin, Chromium, Folate, GI, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Sugar, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Naturade VeganSmart™ All-In-One Nutritional Shake Chai -- 15 ServingsNaturadeWeight ManagementVitamin C, Biotin, Chromium, Folate, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Naturade VeganSmart™ All-In-One Nutritional Shake Chocolate -- 15 ServingsNaturadeWeight ManagementVitamin C, Biotin, Chromium, Folate, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Naturade VeganSmart™ All-In-One Nutritional Shake Vanilla -- 15 ServingsNaturadeWeight ManagementVitamin C, Biotin, Chromium, Folate, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
NUUN Immunity Hydration Single Tube Blueberry Tangerine -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, vitamin E, calcium carbonate, magnesium carbonate, potassium bicarbonate, retinyl acetate, Vitamin A, Selenium, sodium carbonate, ergocalciferol, zinc sulfate2024-11-29 10:47:42
NUUN Vitamins + Caffeine Hydration Single Tube Blackberry Citrus -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins + Caffeine Hydration Single Tube Ginger Lemonade -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Grapefruit Orange -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Strawberry Melon -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
NUUN Vitamins Hydration Single Tube Tangerine Lime -- 10 TabletsNUUNActive Lifestyle & Fitnesscitric acid, d-alpha tocopherol acetate, Vitamin C, Chloride, citric acid, Vitamin E, folic acid, vitamin E, calcium carbonate, potassium bicarbonate, pyridoxal 5-phosphate, Vitamin B6, retinyl acetate, Vitamin A, riboflavin, sodium carbonate, vitamin B6, ergocalciferol2024-11-29 10:47:42
OM Mushroom Morning Blend -- 8.47 ozOMHerbs, Botanicals & HomeopathyVitamin D22024-11-29 10:47:42
Pacific Foods Hemp Milk Unsweetened Vanilla -- 32 fl ozPacific FoodsFood & Beveragestricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Hemp Non-Dairy Beverage Unsweetened Original -- 32 fl ozPacific FoodsFood & BeveragesPhosphorus, tricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Hemp Plant-Based Beverage Original -- 32 fl ozPacific FoodsFood & Beveragestricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Hemp Plant-Based Beverage Vanilla -- 32 fl ozPacific FoodsFood & Beveragestricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Organic Almond Plant-Based Beverage Original -- 32 fl ozPacific FoodsFood & Beveragespotassium citrate, sodium citrate, vitamin D22024-11-29 10:47:42
Pacific Foods Organic Almond Plant-Based Beverage Vanilla -- 32 fl ozPacific FoodsFood & Beveragespotassium citrate, sodium citrate, vitamin D22024-11-29 10:47:42
Pacific Foods Organic Almond Plant-Based Beverage Unsweetened Original -- 32 fl ozPacific FoodsFood & Beveragesvitamin D22024-11-29 10:47:42
Pacific Foods Organic Almond Plant-Based Beverage Unsweetened Vanilla -- 32 fl ozPacific FoodsFood & Beveragesvitamin D22024-11-29 10:47:42
Pacific Foods Organic Coconut Milk Plant-Based Beverage Original -- 32 fl ozPacific FoodsFood & Beveragessodium citrate, tricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Organic Coconut Plant Based Beverage Unsweetened Original -- 32 fl ozPacific FoodsFood & Beveragessodium citrate, tricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Organic Coconut Plant-Based Beverage Unsweetened Vanilla -- 32 fl ozPacific FoodsFood & Beveragessodium citrate, tricalcium phosphate, vitamin D22024-11-29 10:47:42
Pacific Foods Ultra Soy Non-Dairy Beverage Original -- 32 fl ozPacific FoodsFood & BeveragesB2, D-alpha-tocopherol acetate, Vitamin C, Vitamin E, vitamin E, palmitate, Phosphorus, pyridoxine HCL, Vitamin B6, Vitamin A, Riboflavin, tricalcium phosphate, Vitamin B12, vitamin B6, vitamin D22024-11-29 10:47:42
Silk Almondmilk Vanilla -- 6 ContainersSilkFood & Beveragesvitamin E acetate, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, cane sugar, vitamin D22024-11-29 10:47:42
Silk Almondmilk Unsweetened Vanilla -- 1 qtSilkFood & Beveragesvitamin E acetate, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, vitamin D22024-11-29 10:47:42
Silk Organic Soymilk Unsweet -- 32 fl ozSilkFood & BeveragesB2, calcium carbonate, vitamin A palmitate, Vitamin A, Riboflavin, Vitamin B12, vitamin D22024-11-29 10:47:42
Simple Truth Oatmilk Non-Dairy Oat Beverage Original -- 32 fl ozSimple TruthFood & Beveragescalcium carbonate, Phosphorus, potassium phosphate, vitamin A palmitate, Vitamin A, Riboflavin, tricalcium phosphate, Vitamin B12, vitamin D22024-11-29 10:47:42
Simple Truth Unsweetened Coconutmilk -- 32 fl ozSimple TruthFood & BeveragesVitamin C, calcium carbonate, vitamin A palmitate, Vitamin A, Vitamin B12, vitamin D22024-11-29 10:47:42
Simple Truth Organic Unsweetened Soymilk -- 32 fl ozSimple Truth OrganicFood & BeveragesVitamin C, Folate, calcium carbonate, vitamin A palmitate, Vitamin A, vitamin B2, Selenium, Vitamin B12, vitamin D22024-11-29 10:47:42
So Delicious Coconut Milk Unsweetened Vanilla -- 32 fl ozSo DeliciousFood & Beveragescalcium carbonate, magnesium phosphate, vitamin a acetate, Vitamin A, Selenium, calcium phosphate, vitamin b12, vitamin d2, zinc oxide2024-11-29 10:47:42
So Delicious Dairy Free Almond Milk Unsweetened -- 32 fl ozSo DeliciousFood & Beveragesvitamin E acetate, ascorbic acid, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, vitamin D22024-11-29 10:47:42
So Delicious Dairy Free Almond Milk Vanilla -- 32 fl ozSo DeliciousFood & Beveragesvitamin E acetate, Vitamin C, Vitamin E, Vitamin E, calcium carbonate, vitamin A palmitate, Vitamin A, cane sugar, vitamin D22024-11-29 10:47:42
So Delicious Dairy Free Organic Coconut Milk Vanilla -- 32 fl ozSo DeliciousFood & Beveragescalcium carbonate, magnesium phosphate, vitamin A acetate, Vitamin A, Selenium, calcium phosphate, vitamin B12, vitamin D2, zinc oxide2024-11-29 10:47:42
So Delicious Organic Coconut Milk Beverage Unsweetened -- 32 fl ozSo DeliciousFood & BeveragesVitamin C, magnesium phosphate, vitamin A acetate, Vitamin A, Selenium, s, tricalcium phosphate, Vitamin B12, vitamin D2, zinc oxide2024-11-29 10:47:42
So Delicious Organic Dairy Free Coconut Milk Original -- 32 fl ozSo DeliciousFood & Beveragescalcium carbonate, magnesium phosphate, vitamin A acetate, Vitamin A, Selenium, calcium phosphate, Vitamin B12, vitamin D2, zinc oxide2024-11-29 10:47:42
Thompson All In One Multivitamin Iron Free -- 60 CapsulesThompsonVitamins & SupplementsVitamin C, Biotin, cellulose, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Vitanica Luminous® Hair Skin & Nails Support -- 60 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin C, Biotin, calcium ascorbate, Vitamin E, Vitamin E, Selenium, citrate, citrate, Vitamin D22024-11-29 10:47:42
Vitanica Maternal Symmetry™ OB Multivitamin -- 180 Vegetarian CapsulesVitanicaVitamins & SupplementsVitamin C, Biotin, Boron, calcium ascorbate, Chromium, Vitamin E, ferrous fumarate, ferrous succinate, riboflavin-5-phosphate, Folate, Vitamin E, Iodine, Manganese, Vitamin B3, Pantothenic Acid, Vitamin B6, Vitamin A, vitamin B2, Selenium, Thiamin, vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
World Organic Multi Liqui-Mins -- 16 fl ozWorld OrganicVitamins & SupplementsBoron, carbonate, chromium nitrate, Chromium, hydroxide, Iodine, Manganese, Phosphorus, potassium iodide, Selenium, sodium selenite, sorbitol, tricalcium phosphate, Vanadyl Sulfate, ergocalciferol, zinc sulfate2024-11-29 10:47:42
Zhou Supergreens Max Gummies Raspberry -- 60 Vegan GummiesZhouVitamins & Supplementscitric acid, Vitamin C, beta carotene, citric acid, glycerin, Pantothenic Acid, Vitamin B6, sodium citrate, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42

Roles (4)

RoleDescription
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
rodenticideA substance used to destroy rodent pests.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
vitamin DAny member of a group of fat-soluble hydroxy seco-steroids that exhibit biological activity against vitamin D deficiency. Vitamin D can be obtained from sun exposure, food and supplements and is biologically inactive and converted into the biologically active calcitriol via double hydroxylation in the body.
seco-ergostane
hydroxy seco-steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Biochemical pathways: part I0466

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency18.62310.044717.8581100.0000AID485294; AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
TDP1 proteinHomo sapiens (human)Potency19.73470.000811.382244.6684AID686978; AID686979
thioredoxin glutathione reductaseSchistosoma mansoniPotency44.66840.100022.9075100.0000AID485364
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
eyes absent homolog 2 isoform aHomo sapiens (human)Potency79.43281.199814.641950.1187AID488837
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency7.94336.309660.2008112.2020AID720707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)75.80000.11007.190310.0000AID1473738
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)45.00000.17004.559010.0000AID1594139
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)45.00000.17004.559010.0000AID1594139
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)94.00000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)34.50000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)34.50000.03903.55529.8000AID1594140; AID1594141
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (128)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1594136Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID674347Growth inhibition of human HT-29 cells overexpressing VDR gene after 72 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID323923Cytotoxicity against human OR6 cells after 120 hrs by cell viability assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID674348Down-regulation of Gli1 mRNA expression in human U87MG cells at 10 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID323929Cytotoxicity against human OR6 cells after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID323925Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/3-5B/KE/poly cells after 72 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID323932Cytotoxicity against human OR6 cells after 120 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID323928Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 24 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID323922Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1594143Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reducti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID674351Upregulation of CYP24A1 mRNA expression in human HT-29 cells at 10 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1594142Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduct2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594138Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction i2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID674345Binding affinity to full length human VDR expressed in mouse C3H10T1/2 cells assessed as upregulation of CYP24A1 mRNA expression at 5 uM after 24 hrs by RT-PCR analysis relative to control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID674346Growth inhibition of human U87MG cells after 72 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID674352Ratio of CYP24A1 mRNA upregulation in human HT-19 cells to upregulation of CYP24A1 mRNA in human U87MG cells2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID323924Antiviral activity against HCV assessed as suppression of HCV RNA replication in ORN/C-5B/KE/poly cells after 72 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID674349Upregulation of CYP24A1 mRNA expression in human U87MG cells at 10 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID674350Down-regulation of Gli1 mRNA expression in human HT-29 cells at 10 uM after 24 hrs by RT-PCR analysis relative to DMSO-treated control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID674343Inhibition of SMO expressed in mouse C3H10T1/2 cells assessed as down-regulation of Gli1 mRNA expression at 5 uM after 24 hrs by RT-PCR analysis relative to oxysterol2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID674344Binding affinity to full length human VDR by fluorescence polarization-based competitive assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,968)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901622 (54.65)18.7374
1990's170 (5.73)18.2507
2000's377 (12.70)29.6817
2010's687 (23.15)24.3611
2020's112 (3.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.42 (24.57)
Research Supply Index8.17 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index184.81 (26.88)
Search Engine Supply Index3.90 (0.95)

This Compound (54.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials311 (9.60%)5.53%
Reviews271 (8.37%)6.00%
Case Studies180 (5.56%)4.05%
Observational10 (0.31%)0.25%
Other2,467 (76.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]